A few words on this morning's Merck KGaA/SpringWorks deal: Two rare tumor treatments, a takeout consummated after months of rumors, and relief from an M&A drought: https://www.biocentury.com/article/655759/eight-year-run-for-pfizer-spinout-springworks-culminates-in-merck-kgaa-buyout
Comments